Low response to losartan and metformin may be an issue of genetics, not adherence

Website intended for a NZ health professional readership

+Print Archive

Practice

Low response to losartan and metformin may be an issue of genetics, not adherence

17 June 2020

Vanessa Weenink

Wednesday 17 June 2020, 01:30 AM

Cilazapril/hydrochlorothiazide was recently discontinued, providing an opportunity for blood pressure review in many patients

PHARMACOTHERAPY

Pharmacogenomics is an area that continues to expand, especially for medicines that target specific metabolic pathways or are metabolised by
enzymes that have polymorphisms. This article explores how genetic variation can influence two common medicines

Leanne Te Karu and Linda Bryant

Key points Losartan may reduce serum urate levels slightly (by 3–10 per cent), but this is not currently predictable. Losartan is unsuitable a

Pharmacy

Genetics

Print Archive

How to Treat

Prostate cancer

Prostate cancer consultations are common in primary care and there is no one approach to testing and treatment that fits all patients. Urologist Simon van Rij discusses the key considerations and options for personalised care, appropriate investigation and treatment

Wednesday 11 September 2024, 12:45 AM